Novamind reports that four health insurers are now covering its ketamine treatment for Treatment-Resistant Depression.
Articles
Psilocybin therapy boosts cognitive and neural flexibility in depressed patients, study finds
Psilocybin-assisted psychotherapy appears to increase both cognitive and neural flexibility in patients with major depressive disorder, according to new research published in Translational Psychiatry.
Numinus to Host Extension of MAPS-Sponsored MDMA-Assisted Therapy for PTSD Trials
Numinus' Montreal and Vancouver clinics will be host for an extension of the MAPS Phase III clinical trial on MDMA-assisted therapy for PTSD.
Senators Urge Biden To Grant Mass Pardon For Thousands Of Marijuana Cases
A group of senators is urging President Joe Biden to use his executive authority to grant a mass pardon for people with non-violent marijuana convictions, a first step toward righting the wrongs of prohibition.
Compass Pathways Phase II Results: A Disappointment For Some, An Opportunity For Others
Compass Pathways surprised and disappointed the market with its Phase IIb clinical results. Despite the immediate overall selloff on the news, the outlook for many psychedelic stocks is now BETTER.
Levitee Labs Signs Letter of Intent to Acquire a Chain of Specialty Addiction Pharmacies Located in British Columbia
Levitte Labs announce an LOI for the acquisition of 3 more pharmacies specializing in addiction.
Awe-inducing raves are linked to transformative experiences and social bonding, study finds
A study recently published in Frontiers provides new insight into the psychology of raves.
COMPASS Pathways announces positive topline results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression
Compass Pathways reports successful results from its Phase IIb clinical trial of COMP360 for the treatment of Treatment Resistant Depression (TRD).
Michigan Approves Bill Expanding Access to Medical Cannabis Licenses
Michigan Gov. Gretchen Whitmer has signed legislation expanding the number of people eligible for medical cannabis licenses, including those previously barred due to a cannabis-related misdemeanor or felony.
MINDCURE Positioned For Strong Run In 2022 – CEO Q&A
MINDCURE's President and CEO, Kelsey Ramsden updates investors on iSTRYM's launch and rapid penetration, as well as drug development news on several fronts.
Cybin Announces Positive CYB003 Data Demonstrating Significant Advantages Over Oral Psilocybin for Treatment of Mental Health
CYB003 is demonstrating superior treatment properties vs. an oral dosage of psilocybin.
Congressional Lawmakers Approve Marijuana Research Bill For Veterans Despite Biden Administration Opposition
A House committee on Thursday approved a bill that would require the U.S. Department of Veterans Affairs to conduct clinical trials into the therapeutic potential of marijuana for military veterans.
Republican-Led Bill To Legalize And Tax Marijuana Emerges As Alternative To Democratic Measures
A new Republican-led congressional marijuana legalization bill is imminent, Marijuana Moment has learned.
Novamind Reports FY2021 Financial Results and Operating Highlights
Novamind reports its full year results for fiscal 2021, including industry-leading revenue of CAD$6 million.
MINDCURE’s Update Hints At Big Things To Come
As MINDCURE's iSTRYM digital therapeutics platform rapidly gathers momentum, the company looks poised to join the emerging rally in the sector.